– Artblood speeds up the advancement of exclusive extracorporeal blood production technology
– Strengthening cell and cell line technology capabilities by hiring two CTOs… “The world’s only company that can expand red blood cells in vitro”
Artblood (CEO Baek Eun-jung), a biotechnology company that produces blood for transfusion, announced on the 1st that it has newly recruited directors Kim Seon-gyu and Noh Kyung-hwan as CTcO (Chief Technology of Cell line Officer) and CTbO (Chief Technology of Biology Officer), respectively.
Artblood, which possesses a unique technology to implement the blood production process of bone marrow in vitro, secured 13.7 billion won in investment and support funds last year and is currently conducting facility investment and research and development for full-scale in vitro blood production (artificial blood). With this talent recruitment, Artblood plans to further accelerate commercialization by mass producing in vitro blood developed with its own technology.
Kim Seon-gyu CTcO researches and develops cell lines, which are proliferating source cells, and oversees the development of functional cell lines, establishment and management of cell line banking systems. Director Kim majored in microbiology at Seoul National University, and received master’s and doctoral degrees in genetic engineering. He led cell line development and CMC (medicinal manufacturing and quality control)-based technology research at Samsung BioLogics and Samsung Bioepis, and holds 13 registered patents and 16 pending patents.
Noh Kyung-hwan CTbO focuses on the advancement of technology for stably culturing and differentiating functional blood cells in vitro using cell lines built with Artblood’s unique technology, and oversees early development-stage research and strategies so that they can be applied to clinical trials. Director Noh is a veterinarian who completed a combined course in veterinary medicine and master’s and doctoral degrees in veterinary public health at Seoul National University. As a founding member of Kang Stem Biotech, he co-invented the original technology for stem cell isolation and culture, and led most of the development process from the early development stage to the late clinical trial stage of stem cell therapy based on the technology. In addition, he is contributing to the development of the domestic advanced regenerative medicine and advanced biopharmaceutical industries as the head of the cell therapy sub-branch of the advanced biopharmaceutical division of the ‘Dynamic Bio’ of the Korea Biopharmaceutical Association (KOBIA) and as a policy committee member of the policy committee of the Advanced Regenerative Medicine Industry Association (CARM).
Director Kim said, “Artblood is the only company in the world with the ability to proliferate red blood cells outside the body in the artificial blood field,” and “We will help maximize the quality and production efficiency of artificial blood, or bioblood, through advanced cell lines.”
“I am honored to be able to support Artblood, which is developing in vitro produced blood that can solve blood shortage problems and treat various blood-related diseases,” said Director Noh. “We will accelerate the mass production of Bioblood through our experience and know-how in biological research and clinical development.”
Meanwhile, Artblood is developing 'Bioblood', an artificial blood that presents a new paradigm of blood transfusion by implementing the blood production process of bone marrow outside the body. Artblood's artificial blood is expected to have the advantages of being transfused regardless of blood type, blocking the risk of infection at the source, and having a longer survival period in the body than existing donated blood, so it is expected to be a new hope for patients with chronic malignant blood diseases who need to receive regular blood transfusions.
You must be logged in to post a comment.